Close

First results from a large-scale Phase III trial of RTS,S, published online today in the New England Journal of Medicine (NEJM), show the malaria vaccine candidate to provide young African children with significant protection against clinical and severe malaria with an acceptable safety and tolerability profile. The results were announced today at the Malaria Forum hosted by the Bill & Melinda Gates Foundation in Seattle, Washington.

Bionor Pharma is set to initiate a double blinded, randomized and placebo-controlled trial to evaluate HIV-vaccine candidate Vacc-4x in combination with Revlimid.Revlimid is indicated as a treatment for multiple myeloma and anemia due to myelodysplastic syndrome linked with a deletion in the long arm of the fifth chromosome.

More Articles ...

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok